ERBB2 and cancer: Monoclonal immunoglobulin preparations or pharmaceuticals with binding-avidity for HER2/neu (e.g. anti-HER2/neu: trastuzumab, pertuzumab), EGFR (e.g. anti-EGFR: cetuximab, gefitinib) [1]–[4], HER2/neu and EGFR (e.g. anti-HER2/neu and anti-EGFR: panitumumab) [3]–[6] IGF-1R, VEGFR and inhibitors of trophic membrane receptors can all potentially be effective treatment options for certain neoplastic conditions including cancer affecting the breast, intestinal tract, lung or prostate.